CYP4F8 can be identified as a novel therapeutic target in prostate cancer and is associated with the pharmacokinetics and toxicities of methotrexate, a fundamental drug for osteosarcoma [44, 45]. The gene discussed is CYP4F8; the disease is prostate carcinoma.